Personalized mRNA cancer vaccine reduces melanoma recurrence risk in late trial

Adding an individualized genetic vaccine to standard immunotherapy reduced the chance of skin cancer returning or causing death by 42 percent after surgical removal.

When a surgeon cuts out a dangerous skin tumor, the procedure rarely marks the end of the threat.¹ Even after visible melanoma lesions are removed from the skin or surrounding lymph nodes, microscopic cancer cells can remain hidden elsewhere in the body.¹ These stray cells often lie dormant before multiplying months or years later, frequently spreading to vital organs such as the lungs, liver, or brain.¹ For decades, medicine relied on broad-spectrum therapies to clean up those remnants, but cancer cells often mutate in ways that make them invisible to the standard immune defenses.

To stop cancer from returning after surgery, the body needs a way to recognise and destroy lingering malignant cells before they form new tumors. In a healthy immune system, white blood cells called T cells inspect cellular fragments, looking for foreign proteins. Because cancer originates from a patient's own tissue, tumors often present proteins that look almost identical to healthy tissue, allowing rogue cells to evade immune scrutiny. Adding synthetic flags that teach T cells exactly what the patient's specific tumor looks like can direct immune cells to hunt down hidden cancer cells throughout the body.

A late-stage clinical trial evaluating this individualized approach has demonstrated that a tailored messenger RNA vaccine can significantly lower the risk of cancer returning. The study examined intismeran autogene, an investigational therapy developed jointly by pharmaceutical manufacturers Merck and Moderna, given alongside the established immunotherapy drug pembrolizumab, sold under the brand name Keytruda.¹ In patients with resected stage IIB through stage IV cutaneous melanoma, adding the custom vaccine reduced the risk of disease recurrence or death by 42 percent compared to pembrolizumab given alone.¹

How does a tailored vaccine train the immune system?

The personalized therapy works by turning a patient's specific genetic mutations into a set of molecular targets for immune cells.¹² Cancer occurs when DNA alterations cause cells to grow uncontrollably, and these alterations frequently produce abnormal protein fragments known as neoantigens.³¹ Because every patient's tumor acquires an idiosyncratic collection of mutations, neoantigens differ widely from person to person. Standard vaccines expose the body to a shared, universal antigen, whereas an individualized neoantigen therapy manufactures a custom instruction set for each individual.

To build intismeran autogene, researchers obtain a surgical biopsy of the removed tumor and take a normal DNA sample from the patient's healthy tissue.¹² Automated sequencing systems compare the two genetic profiles to pinpoint mutations present only inside the malignant cells.²¹ Scientists then select up to 34 neoantigens judged most likely to provoke an active T-cell response and encode their genetic blueprints into a single strand of synthetic messenger RNA.¹² Once injected into muscle tissue, the body translates this synthetic sequence into neoantigen proteins, which are displayed on cell surfaces to train circulating T cells to spot and eliminate matching tumor cells.¹³

This vaccination regimen is paired with pembrolizumab to prevent the cancer from switching off the immune response.¹³ Tumors often protect themselves by activating a receptor called programmed death receptor-1, or PD-1, on the surface of T cells, which acts as a molecular brake that halts immune attacks.¹ Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, releasing that brake so activated T cells can destroy malignant cells.¹ The combination provides both the navigation coordinates to identify the tumor and the biochemical permission to attack it.

What did the Phase 3 clinical trial show?

The late-stage trial, named INTerpath-001, evaluated whether combining intismeran autogene with pembrolizumab could improve outcomes in 1,137 patients whose high-risk cutaneous melanoma had been completely removed by surgery.¹² Investigators randomly assigned participants in a two-to-one ratio to receive either the combination therapy or pembrolizumab paired with an inactive placebo.¹² Patients in the combination group received nine doses of intismeran autogene administered once every three weeks, alongside pembrolizumab infusions given every six weeks for approximately one year.¹

Over a median follow-up period of 24.6 months, patients who received the combination therapy showed a 42 percent reduction in the hazard of disease recurrence or death relative to those treated with pembrolizumab alone.¹² In the trial's intention-to-treat population, 82.2 percent of patients receiving the vaccine and pembrolizumab remained alive without disease recurrence at two years, compared to 70.0 percent of patients receiving pembrolizumab and placebo.¹² The hazard ratio for recurrence or death was 0.58, with a 95 percent confidence interval spanning 0.45 to 0.75.¹

The trial also measured distant metastasis-free survival, tracking whether cancer returned in distant organs away from the primary surgical site.¹ After two years of follow-up, 88.5 percent of patients in the combination group remained free of distant metastasis or death, compared with 80.2 percent of patients in the monotherapy group.¹² That difference represented a 38 percent reduction in the risk of distant metastasis or death, with a hazard ratio of 0.62 and a 95 percent confidence interval from 0.45 to 0.85.¹² Professor Georgina Long, the study's principal investigator and medical director of Melanoma Institute Australia, noted that the findings support an individualized approach that tailors adjuvant treatment to the unique mutational signature of a patient's tumor.

What are the limitations of the current findings?

The data from the trial represent mid-term survival endpoints rather than a completed measure of total cure or overall survival. While investigators observed a favorable trend in overall survival among patients receiving the combination, those figures are not yet statistically mature because many trial participants remain alive and under monitoring.¹ Long-term outcomes will require additional years of follow-up to determine whether the delay in disease recurrence translates into an extended lifespan.

The protective effect of the combination therapy also required several months to establish. During the first six months of treatment, while patients were still undergoing the sequence of mRNA injections, the rate of recurrence or death was nearly identical between the two study arms, showing a hazard ratio of 0.99.¹ The separation in survival curves emerged only after that initial six-month period had elapsed, at which point a sensitivity analysis demonstrated a 58 percent reduction in the risk of recurrence or death for the combination group compared to pembrolizumab alone.¹

Additionally, while the combination showed clear statistical significance, the relative risk reductions were somewhat lower than those reported in an earlier, smaller Phase 2b trial named KEYNOTE-942.²⁴ That earlier study, which followed 157 patients over five years, observed a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in distant metastasis or death.² Trial results from larger and more diverse cohorts frequently settle at more modest effect sizes as patient populations broaden.

Adverse effects were also frequent across both groups, reflecting the biological activity of stimulating the immune system. Treatment-related adverse events occurred in 95.8 percent of patients receiving the combination and in 90.0 percent of patients receiving pembrolizumab alone.¹ Severe reactions classified as grade 3 to grade 5 occurred in 14.2 percent of combination patients compared to 13.4 percent of monotherapy patients, with pyrexia, injection site pain, and fatigue representing the most common side effects from the vaccine.¹

Where does individualized mRNA therapy go next?

Regulatory authorities are currently reviewing data from the INTerpath-001 trial as Merck and Moderna seek formal marketing approval for intismeran autogene in resected melanoma.¹² Melanoma remains the deadliest form of skin cancer, accounting for more than 338,000 new diagnoses worldwide in 2024 and an estimated 112,000 cases in the United States in 2026.¹² If authorized by regulators, intismeran autogene would become the first personalized mRNA cancer vaccine cleared for routine medical use following surgery.

Researchers are also testing whether the same neoantigen strategy can prevent recurrences in other common cancers. The joint development program between Merck and Moderna includes nine active clinical trials across multiple tumor types, encompassing three Phase 3 trials in non-small cell lung cancer as well as studies in bladder cancer, renal cell carcinoma, and pancreatic tumors.¹⁴ Because the manufacturing platform builds each therapy directly from tumor sequence data, the fundamental process remains identical regardless of where a patient's primary cancer first emerged.

Save this story

The record

33 sentences trace to 4 sources.

All 4Documents 1Records 0Reporting 3People 0

1. 1 M merck.com Third-party reporting · merck.com · 22 Oct 2026 Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium - Merck.com See the source
2. 2 BM Beth Mole Document · arstechnica.com · 22 Oct 2026 Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% See the source
3. 3 M melanoma.org.au Third-party reporting · melanoma.org.au · 29 May 2023 Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial See the source
4. 4 M merck.com Third-party reporting · merck.com · 20 Jan 2026 Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection - Merck.com See the source